Conformal Medical, a Nashua, NH-based medical device company, raised $35M in Series D funding.
The round was led by SPRIG Equity with participation from all major Series C investors.
The company intends to use the funds to complete the clinical trial to demonstrate its safety profile and ability to offer solutions that address unmet clinical needs to improve the way structural heart diseases are diagnosed and treated.
Founded in 2016 and led by CEO James Reinstein, Conformal Medical is a medical device company developing devices to prevent stroke in patients with non-valvular Afib. Its proprietary technology is intended to make LAAO a same day, single operator procedure. The CLAAS device further aims to simplify the procedure by allowing off-axis positioning while providing a more uniform seal. The CLAAS implant may also be able to eliminate the need for procedural transesophageal echocardiogram so that physicians may perform the procedure without general anesthesia.
RELATED: Strive Health scores $166M to scale value-based kidney care
The round reflects the progress and achievements made since its last funding round, which includes the initiation of the CONFORM Clinical Trial. The CONFORM Trial is the company’s pivotal trial evaluating the safety and efficacy of the CLAAS® System compared to other commercially available LAAO devices and will support U.S. Food and Drug Administration (FDA) pre-market approval. The CLAAS System is designed to seal the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (Afib) to reduce the risk of stroke without the need for anticoagulants.
